Radiation dose in Hodgkin's disease: Are we overtreating?

Clinical Oncology

Volumn 9, Issue 3, 1997, Pages 155-157

  Moody, A M ^a   Williams, M V ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RADIOTHERAPY; HODGKIN DISEASE; PRIORITY JOURNAL; RADIATION DOSE; REVIEW;

EID: 0030851156     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(97)80071-4     Document Type: Review

References (26)

1. Hope-Stone HF. The place of radiotherapy in the management of localised Hodgkin's disease. Clin Radiol 1981;32:519-22.
2. Haybittle JL, Hayhoe FGJ, Easterling MJ, et al. Review of the British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index. Lancet. 1985;i:967-72.
3. Brizel MD, Winer EP, Prosnitz LR, et al. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. Int J Radiat Oncol Biol Phys; 19:535-42.
4. Hunger SP, Link MP, Donaldson SS. ABVD/MOPP and low-dose involved-field radiotherapy in paediatric Hodgkin's disease: the Stanford experience. J Clin Oncol 1994; 12:2160-6.
5. Vijayakumar S, Myrianthopoulos LC. An updated dose-response analysis in Hodgkin's disease. Radiother Oncol 1992;24:1-13.
6. Brincker H, Bentzen SM. A re-analysis of available dose-response and time-dose data in Hodgkin's disease. Radiother Oncol 1994;30:227-30.
7. Bates NP, Williams MV, Bessell EM, et al. Efficacy and toxicity of vinblastine, bleomycin and methotrexate with involved-field radiotherapy in clinical Stage IA and IIA Hodgkin's disease: a British National Lymphoma Investigation pilot study. J Clin Oncol 1994;12:288-96.
8. Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomised trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993;11:2258-72.
9. Hoppe RT. Patterns of Care study newsletter. American College of Radiology. 1990-91;(3).
10. Kaplan HS. Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease. Cancer Res 1966;26: 1221-4.
11. Kaplan HS. Hodgkin's disease. 2nd ed. Harvard University Press, Cambridge, Massachusetts, London. England. 1980: 366-441.
12. Fletcher GH, Shukovsky LJ. The interplay of radio-curability and tolerance in the irradiation of human cancers. J Radiol Electrol 1975;56:383-400.
13. Schewe KL, Reavis J, Kun LE, et al. Total dose, fraction size, and tumour volume in the local control of Hodgkin's disease. Int J Radiat Oncol Biol Phys 1988;15:25-8.
14. Thar TL, Million RR, Hausner RJ, et al. Hodgkin's disease, Stages I and II: relationship of recurrence to size of disease, radiation dose and number of sites involved. Cancer 1979;43:1101-5.
15. Hanks GE, Kinzie JJ, Herring DF, et al. Patterns of care outcome studies in Hodgkin's disease: results of national practice and implication for management. Cancer Treat Rep 1982;66:805-8.
16. Schewe KL. A step towards ending the controversies in Hodgkin's disease. Int J Radiat Oncol Biol Phys 1989; 17:1123.
17. Raubitschek A, Glatstein E. The never-ending controversies in Hodgkin's disease. Int J Radiat Oncol Biol Phys 1989; 17:1115-7.
18. Carmel RJ, Kaplan HS. Mantle irradiation in Hodgkin's disease: an analysis of technique, tumour eradication and complications. Cancer 1976;37:2813-25.
19. Rosenberg I, Vijayakumar S, Speibring D. The use of a negative beam to simulate a midline block. Med Dosim 1991;16:233-6.
20. David JB, Reiner B. Depth dose under narrow shielding blocks: a comparison of measured and calculated dose. Radiother Oncol 1995;34:219-27.
21. Janjan NA, Zellmer DL. Is the dose-response relationship for local control of Hodgkin's disease obscured by lung inhomogeneity corrections? Radiother Oncol 1991;22:195-200.
22. Boivin J-F, Hutchinson GB, Lubin JH, et al. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 1992;69:1241-7.
23. Dubray B, Henry-Amar M, Meerwaldt JH, et al. Radiation-induced lung damage after thoracic irradiation for Hodgkin's disease: the role of fractionation. Radiother Oncol 1995;36:211-7.
24. Hancock SL, Cox RS, McDougall IR. Thyroid disease after treatment of Hodgkin's disease. N Engl J Med 1992;325:599-605.
25. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, et al. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. BMJ 1992;304:1137-43.
26. Hancock BL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993;270:1949-55.